Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SHBG | P04278 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24794287 | 0.98 | SHBG (0.37) | HRH3CYP2D6SHBGKDM1AOPRM1 | |
| SCHEMBL24792865 | 0.93 | HRH3 (0.36) | HRH3CYP2D6SHBGKDM1AOPRM1 | |
| SCHEMBL839914 | 0.93 | KDM1A (0.33) | HRH3CYP2D6SHBGKDM1AALDH1A1 | |
| SCHEMBL24793681 | 0.91 | HRH3 (0.35) | HRH3CYP2D6SHBGOPRM1OPRL1 | |
| SCHEMBL24303716 | 0.91 | HRH3 (0.35) | HRH3CYP2D6SHBGOPRM1OPRL1 | |
| SCHEMBL840364 | 0.89 | HRH3 (0.34) | HRH3CYP2D6KDM1AALDH1A1KCNH2 | |
| SCHEMBL408516 | 0.89 | CHRNA7 (0.34) | HRH3CYP2D6KDM1AALDH1A1KCNH2 | |
| SCHEMBL840274 | 0.83 | KAT2B (0.33) | HRH3CYP2D6 | |
| SCHEMBL26948792 | 0.80 | DRD2 (0.35) | HRH3CYP2D6KDM1AOPRM1OPRL1 | |
| SCHEMBL26948799 | 0.80 | DRD2 (0.35) | HRH3CYP2D6KDM1AOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015229-A1 | PROTEASE/ENZYME CLEAVABLE LINKER-PAYLOADS AND PROTEIN CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | CIDARA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | BIAL R&D INVEST S A (PT) | 2022-12-22 | — | — | US | disclosed |
| US-9440938-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8623903-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | KUGIMIYA AKIRA (JP) | 2012-06-07 | — | — | US | disclosed |
| US-8153793-B2 | Sulfonamide derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8143285-B2 | Indolecarboxylic acid derivative having PGD2 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158833-A1 | SULFONAMIDE DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, PTGDR2, CNR2 | HRH3 34/4885CYP2D6 451/4885SHBG 1441/4885 |
| US-20220402901-A1 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | ASAH2, ASAH1, GBA1 | HRH3 476/4885CYP2D6 2874/4885SHBG 4874/4885 |
| US-20090105274-A1 | Indolecarboxylic Acid Derivative Having PGD2 Receptor Antagonistic Activity | PTGDR, CYSLTR1, CNR1 | HRH3 13/4885CYP2D6 512/4885SHBG 3345/4885 |
| US-20230364251-A1 | METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES | DNPEP, NPEPPS, DHFR | HRH3 4395/4885CYP2D6 738/4885SHBG 1126/4885 |
| US-20120142687-A1 | INDOLECARBOXYLIC ACID DERIVATIVE HAVING PGD2 RECEPTOR ANTAGONISTIC ACTIVITY | PTGDR, CYSLTR1, CYSLTR2 | HRH3 15/4885CYP2D6 498/4885SHBG 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.